Clinical TrialJun 12, 2026, 02:26 PM
Ionis Reports Positive Longer-Term Olezarsen Data for sHTG
AI Summary
Ionis Pharmaceuticals announced positive longer-term data from the open-label extension study (CORE-OLE) evaluating olezarsen in people with severe hypertriglyceridemia (sHTG). The data, presented at the National Lipid Association Scientific Sessions, showed mean hepatic fat fraction (HFF) levels returning toward baseline after 24 months of treatment with the 80 mg dose. Olezarsen maintained a favorable safety profile, and the study demonstrated high patient retention with over 90% of eligible patients remaining in the CORE-OLE.
Key Highlights
- Mean hepatic fat fraction (HFF) levels returned toward baseline after 24 months of 80 mg olezarsen treatment.
- Patients transitioning from 50 mg to 80 mg showed less pronounced mean HFF changes.
- Olezarsen continued to demonstrate a favorable safety profile with longer-term treatment.
- Patient retention in the CORE-OLE study was very high, exceeding 90% of eligible patients.
Price Impact
More from IONS